ResMed Stock

$270.93

1.31%

NYSE, Sep 02, 10:00 pm CET

ISIN

US7611521078

Symbol

RMD

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

ResMed Stock price

$270.99

+87.99 48.08% 5Y

NYSE, Closing price Tue, Sep 02 2025

-3.52 1.28%

ISIN

US7611521078

Symbol

RMD

Reports

Quarter | Annual

Index

NYSE Composite, S&P 500

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$39.7b

Enterprise Value

$39.1b

Net debt

positive

Cash

$1.2b

Shares outstanding

146.4m

Valuation (TTM | estimate)

P/E

28.5 | 24.7

P/S

7.7 | 7.0

EV/Sales

7.6 | 6.9

EV/FCF

23.7

P/B

6.7

Dividends

DPS

$2.12

Yield 1Y | 5Y

0.8% | 0.8%

Growth 1Y | 5Y

10.4% | 6.3%

Payout 1Y | 3Y

22.3% | 25.8%

Increased

4 Years

Financials (TTM | estimate)

Revenue

$5.1b | $5.7b

EBITDA

$1.7b | $2.2b

EBIT

$1.7b | $2.0b

Net Income

$1.4b | $1.6b

Free Cash Flow

$1.7b

Growth (TTM | estimate)

Revenue

9.8% | 9.8%

EBITDA

21.0% | 25.5%

EBIT

21.8% | 17.9%

Net Income

37.2% | 14.7%

Free Cash Flow

28.3%

Financial Health

Equity Ratio

73.0%

Return on Equity

23.5%

ROCE

23.6%

ROIC

22.0%

Debt/Equity

0.1

EPS

$9.5

FCF per Share

$11.3

Short interest

7.0%

Employees

10k

Rev per Employee

$520.0k

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Get Started for Free Today

ResMed Stock Analysis

Unlock Scores for Free

??

23 Analysts have issued a ResMed forecast:

16x Buy

70%

6x Hold

26%

More details on Analyst Estimates Including Price Targets

23 Analysts have issued a ResMed forecast:

Buy

70%

Hold

26%

Sell

Analyst Estimates with Stock Price Targets

Financial data from ResMed

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	5,146 5,146	10% 10% 100%
- Direct Costs	2,093 2,093	3% 3% 41%
Gross Profit	3,053 3,053	15% 15% 59%
- Selling and Administrative Expenses	991 991	8% 8% 19%
- Research and Development Expense	331 331	8% 8% 6%
EBITDA	1,731 1,731	21% 21% 34%
- Depreciation and Amortization	45 45	3% 3% 1%
EBIT (Operating Income) EBIT	1,686 1,686	22% 22% 33%
Net Profit	1,401 1,401	37% 37% 27%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

ResMed Stock News

Neutral

GlobeNewsWire

●

7 days ago

Obstructive Sleep Apnea Expected to Affect Nearly 77 million U.S. Adults by 2050, New Resmed Study Finds

SAN DIEGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark study in The Lancet Respiratory Medicine projecting a significant rise in obstructive sleep apnea (OSA) in the United States over the next three decades due to a variety of fact...

Positive

Seeking Alpha

●

7 days ago

ResMed: A Dividend Opportunity In The MedTech Space As The Company Grows

For my first rating of ResMed, I'm calling a buy, agreeing with today's consensus from Wall St. and more confident than the quant system, which said hold. Key upside factors are new business acquisitions and FDA approvals, proven demand momentum so far, and revenue diversification along with strong profit margins in its peer group. RMD is a proven dividend grower over 10 years while also having...

Neutral

GlobeNewsWire

●

15 days ago

Resmed Announces Election of Nicole Mowad-Nassar to Board of Directors and Upcoming Retirement of Rich Sulpizio

SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced the election of Nicole Mowad-Nassar to its board of directors, effective August 15, 2025. The company also announced that board member Rich Sulpizio is thanked for two decades of contributions to Resmed, and will retire from the board, not standing for reelection at the 2025 Annual Meeting of Stockholders,...

More ResMed News

Company Profile

ResMed, Inc. engages in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through the following segments: Sleep and Respiratory Care, and SaaS. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The SaaS segment engages in the supply of business management software as a service to out-of-hospital health providers. Its product portfolio includes devices, diagnostic products, mask systems, headgear and other accessories, and dental devices. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Head office	United States
CEO	Mick Farrell
Employees	9,980
Founded	1989
Website	www.resmed.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now